OHDSI MEETINGS THIS WEEK
OHDSI STATEMENT ON COVID-19: OHDSI is committed to doing what it can to support and inform the COVID-19 pandemic response, and will prioritize activities aligned to this effort. As we adjust to the current global situation, the OHDSI community will continue to have our regular Tuesday community calls, as well as our various working group calls. Understandably, some calls could be postponed or cancelled due to issues surrounding COVID-19, so we ask that you continuously check the OHDSI forums, weekly digest and social channels for updated information. OHDSI is a virtual community, so we are equipped to continue collaboration during this challenging time.
OMOP CDM Oncology WG - Genomic Subgroup Meeting - Tuesday at 9am EThttps://us04web.zoom.us/j/412862164?pwd=NmpEWTdTQlB4N3VxT0tQRXdDWlg0dz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
Gold Standard Phenotype Library WG - Tuesday at 11am EThttps://gatech.webex.com/gatech/j.php?MTID=mdd4af3e9b84212fc7df3eb0150703df5 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:gold-library-wg
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=96139.930901412523321531221112212141232121131213113112112121536 https://www.ohdsi.org/web/wiki/doku.php?id=projects:ohdsi_community
CDM Working Group - Tuesday at 1pmEThttps://meet.lync.com/jnj-its/mblacke/C8SP52P1 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:cdm-wg
Oncology WG - Development Subgroup Meeting - Wednesday at 10am EThttps://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:development_schedule https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
Natural Language Processing WG - Wednesday at 2pm EThttps://global.gotomeeting.com/join/707196421 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:nlp-wg
OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am EThttps://us04web.zoom.us/j/755053125?pwd=V0dOZVVnY3RMRWgxMVVGTDdVbnA1UT09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
China WG - Friday at 10am EThttps://global.gotomeeting.com/join/721873621 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:china-wg
You can find a full list of upcoming OHDSI meetings here: https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit
ANNOUNCEMENTS
OHDSI F2F & 2020 US Symposium To do our part in reducing the spread of COVID-19 we have decided not to hold a F2F meeting this summer. However, planning for the 2020 U.S. Symposium, which will take place October 18-21st, is underway, and we will be sharing details when they become available.
COVID-19 Virtual Study-a-thon - To contribute to the COVID-19 response, the OHDSI community hosted a virtual study-a-thon on March 26-29th. For updates and videos from this event, check out this forum post: FINAL GLOBAL UPDATE: #OHDSICOVID19 Study-A-Thon (video link posted)
If you’re going through hell, keep going.
COMMUNITY PUBLICATIONS
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.
J Sultana, G Scondotto, PM Cutroneo, F Morgante and G Trifirò,
Frontiers in pharmacology , 2020
Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these diseases. Two recent case reports have found a potential link between intravitreal anti-VEGF use and Parkinson's disease (PD) and dementia.To evaluate disproportionality in a large spontaneous reporting database concerning intravitreal anti-VEGF drugs and PD or dementia, and related conditions.Using VigiBase, individual case safety reports (ICSRs) attributed to intravitreal ranibizumab, aflibercept, pegaptanib, and bevacizumab were identified from 2010 to 2016. Within Standardised Narrow Medical Dictionary for Regulatory Activities (MedDRA®) Queries (SMQs) for "Parkinson-like events" and "Dementia," suspected events were identified using preferred terms (PTs). The Proportional Reporting Ratio (PRR) was estimated with the lower 95% confidence intervals (CIs) for all drug-event pairs with ≥3 suspected events. The vigiGrade completeness score was reported for the ICSRs. The analyses were repeated, including only persons aged 65 and over.Out of 18.9 million ICSRs, 7,945 (0.004%) concerned intravitreal anti-VEGF drugs. Of these, 27 (0.34%) were identified concerning the SMQs "Dementia" (N = 17, 62.96%) and "Parkinson-like events" (N = 10, 37.94%) in persons of all ages. Among persons age 65 and over, 4,758 (59.88% of relevant ICSRs) ICSRs were identified for anti-VEGF drugs. When restricting disproportionality analysis to persons aged 65 and over, no disproportionality was seen for any of the drug-event pairs at the level of SMQ. However, on analysing disproportionality by PT, a potential signal emerged for intravitreal ranibizumab and Parkinson's disease [N = 6 ICSRs; PRR: 3.05 (95% CI: 1.36-6.81)]. In general, the vigiGrade completeness score was low for all the ICSRs of interest, as no ICSR had a score >0.8.Present findings suggest a potential signal for Parkinson's disease related to intravitreal ranibizumab. This is supported by several biologically plausible mechanisms but requires confirmation through pharmacoepidemiological studies, especially because of the low number of cases.
A Framework for Improving Characterization of Obstetric Hemorrhage Using Informatics Data.
D Goffman, AM Friedman, JJ Sheen, A Kessler, D Vawdrey, R Green, ME D'Alton and M Oberhardt,
Obstetrics and gynecology , 2019 12
To characterize postpartum hemorrhage trends and outcomes using bioinformatics and electronic health record data.This retrospective analysis included all women who delivered in a four-hospital system from July 2014 to July 2017 during implementation of a postpartum hemorrhage bundle. Data on billing codes, uterotonics, transfusion, intrauterine tamponade device placement, and hysterectomy were analyzed. A framework of four postpartum hemorrhage levels based on hemorrhage interventions was created using this informatics data. Levels were analyzed in relation to hematocrit drop from the highest predelivery to the lowest postpartum level. Changes in treatment patterns were assessed with risk-adjusted regression models with adjusted odds ratios (aOR) and 95% CI as the measures of effect. Postpartum hemorrhage-associated severe maternal morbidities were analyzed with adjusted models.The cohort included 43,657 deliveries. Four mutually exclusive postpartum hemorrhage levels were created based on informatics and billing criteria. Level 1: receipt of uterotonic other than oxytocin (3.7% of patients); level 2: billing diagnosis code for postpartum hemorrhage (3.0% of patients); level 3: placement of the intrauterine tamponade device, transfusion of 1-3 units red blood cells (RBCs), or both (1.8% of patients); and Level 4: hysterectomy, 4 or more units RBCs, or both (0.6% of patients). Higher postpartum hemorrhage levels were associated with higher hematocrit drops. In postpartum hemorrhage levels 1 through 4, 1.6%, 5.6%, 30.2%, and 30.7% of women had hematocrit drops greater than 40%, compared with 0.4% of women without postpartum hemorrhage. Over the course of the study, hematocrit drops within a given level did not change. Postpartum hemorrhage interventions such as uterotonics increased significantly (aOR 1.16, 95% CI 1.11-1.21, with aOR denoting change in outcome across 1 year). Although severe maternal morbidity did not change significantly, risk of hysterectomy decreased significantly (aOR 0.52, 95% CI 0.40-0.68).Postpartum hemorrhage can be characterized in a granular fashion with informatics data. Informatics data are becoming increasingly available and can provide detailed assessment of postpartum hemorrhage incidence, management, and outcomes to facilitate surveillance and quality improvement.
